CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis

Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25.

Authors

Liat Shargian^{1

2}, Pia Raanani^{1

2}, Moshe Yeshurun^{1

2}, Anat Gafter-Gvili^{1

2

3}, Ronit Gurion^{1

2}

Affiliations

¹ Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
² Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Medicine A, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.

PMID: 36281746
DOI: 10.1111/bjh.18506

No abstract available

Keywords: B-cell; CAR-T; CD19; chimaeric antigen receptor; diffuse large cell; lymphoma; meta-analysis; refractory relapse.

Publication types

Meta-Analysis
Systematic Review
Letter
Comment

MeSH terms

Antigens, CD19
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
Standard of Care

Substances

Receptors, Chimeric Antigen
Antigens, CD19
Receptors, Antigen, T-Cell